43 related articles for article (PubMed ID: 30932408)
1. Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Benesova A; De Santis S; Polivkova V; Pecherkova P; Krizkova J; Suchankova P; Monaldi C; Klamova H; Srbova D; Zizkova H; Hochhaus A; Soverini S; Machova Polakova K
Am J Hematol; 2024 Apr; 99(4):759-762. PubMed ID: 38314531
[No Abstract] [Full Text] [Related]
2. The Mozart effect in chronic myeloid leukaemia.
Stentoft J
Br J Haematol; 2024 Apr; 204(4):1139-1140. PubMed ID: 38375783
[TBL] [Abstract][Full Text] [Related]
3. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ; Kim JJ; Pyne D; Travas A; Ambalavanan A; Kimura S; Deininger MW; Kim JW; Kim DDH
Leukemia; 2024 Feb; 38(2):412-415. PubMed ID: 38155246
[No Abstract] [Full Text] [Related]
4. Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G
Langabeer SE; Macleod S; Bhreathnach Ú; Fadalla K
Case Rep Hematol; 2023; 2023():6673144. PubMed ID: 37123466
[TBL] [Abstract][Full Text] [Related]
5. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S
Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669
[No Abstract] [Full Text] [Related]
6. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
7. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Gniot M; Wasilewska EM; Lewandowski K
Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
[No Abstract] [Full Text] [Related]
8. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
Langabeer SE; Haslam K; Crampe M; MacDonagh B; McHugh J
Exp Oncol; 2019 Mar; 41(1):82-83. PubMed ID: 30932408
[No Abstract] [Full Text] [Related]
10. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
Kantarjian H; Branford S; Breccia M; Cortes J; Haddad FG; Hochhaus A; Hughes T; Issa GC; Jabbour E; Nicolini FE; Sasaki K; Xavier-Mahon F
Leukemia; 2024 May; 38(5):947-950. PubMed ID: 38531949
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
